On February 21, 2023 Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported that the Company plans to participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023 taking place at Citi HQ Conference Center in New York City (Press release, Alpha Tau Medical, FEB 21, 2023, View Source [SID1234627503]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference:

Date: Wednesday, March 1, 2023

Location: Citi HQ Conference Center

If you would like to schedule a 1:1 meeting, please contact your Citi representative.

On February 21, 2023 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, reported that it will release financial results for the fourth quarter and year ended December 31, 2022 before the open of trading on Monday, March 6 (Press release, Biodesix, FEB 21, 2023, View Source [SID1234627493]). Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. Eastern Time on the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.

On February 21, 2023 ADC Therapeutics SA (NYSE: ADCT) reported that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2022 and provide business updates (Press release, ADC Therapeutics, FEB 21, 2023, View Source [SID1234627492]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

On February 21, 2023 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, reported that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023 (Press release, Natera, FEB 21, 2023, View Source [SID1234627491]). Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Earnings Conference Call Information:

Event:

Natera’s Fourth Quarter and Year-End 2022 Financial Results

Date:

Tuesday, Feb. 28, 2023

Time:

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In:

1 (888) 770-7321, Domestic

1 (929) 201-7107, International

Conference ID:

7684785

Webcast:

View Source

A webcast replay will be available at investor.natera.com.

On February 21, 2023 Nordic Nanovector ASA (OSE: NANOV) reported that it will report its results for the second half and full year 2022 on Tuesday, 28 February 2023 (Press release, Nordic Nanovector, FEB 21, 2023, View Source [SID1234627490]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A presentation by Nordic Nanovector’s interim CEO & CFO, Ludvik Sandnes, will be held in-person and webcast live beginning at 8:30am CET.

VENUE: ADVOKATFIRMAET CLP DA, Sommerrogata 13, 0255 Oslo

Questions can be submitted in advance to [email protected]

The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2022 from 7:00am CET the same day.

IR enquiries

Ludvik Sandnes, Interim CEO & CFO
+47 907 43 017
[email protected]